Role of Foxo1 gene expression in mechanism of antihypertrophic action of metformin in cardiomyocytes
Journal Title: Міжнародний ендокринологічний журнал - Year 2018, Vol 14, Issue 7
Abstract
Background. Diabetic cardiomyopathy is the leading cause of mortality in patients with type 2 diabetes mellitus. Hypertrophy of cardiomyocytes is one of the main pathomorphological signs of diabetic cardiomyopathy development. Metformin, the first-line drug for the treatment of type 2 diabetes mellitus, along with hypoglycaemic effects, exerts cardioprotective effects. However, the mechanism of metformin action in cardiomyocytes remains unclear. The purpose of the study was to investigate the role of Foxo1 gene expression in the mechanism of antihypertrophic action of metformin in cardiomyocytes. Materials and methods. H9C2 cells were transfected with siRNA Fохо1 and siRNA negative control. Cells were deprived in 0% medium for 24 hours, treated with metformin (5mM) 30 min before cell stress, then put into hypoxic chamber for 16 hours and reoxygenated for 4 hours. Cell area was quantified using ImageJ. Knockdown efficiency was confirmed by real time polymerase chain reaction. Results. At the normal functioning of Fохо1 gene, metformin has the expressed antihypertrophic action under hypoxia. However, blocking Fохо1 gene expression deprives preparation of this effect and causes the hypertrophy of Н9С2 cells in all conditions of the experiment. Conclusions. The strong hypertrophic response in the group of H9C2 cells transfected with siRNA Foxo1 cultured under hypoxia with metformin treatment may be a result of following mechanisms: a) metformin prevents hypertrophy through Foxo1 pathway, thus, Foxo1 silencing totally blocked metformin protective effects on H9C2 hypertrophy; b) metformin protects against hypoxia independently of Foxo1 pathway, therefore, strong hypertrophy of metformin-treated cells incubated in hypoxia is the result of Foxo1 knockdown, a potent hypertrophic stimulus. Consequently, further investigations are still required to clarify the mechanisms by which metformin exerts its cardioprotective effects.
Authors and Affiliations
N. V. Pasiechko, H. Ya. Loi, M. M. Korda, O. M. Oleshchuk
Keywords
Related Articles
- EP ID EP432728
- DOI 10.22141/2224-0721.14.7.2018.148779
- Views 65
- Downloads 0
Analysis of the Implementation of Standardized Clinical Protocol «Diabetes Mellitus Type 2» by Quality Indicators in Institutions of Kyiv Region
In Ukraine, a standardized clinical protocol (SCP) to provide medical care in diabetes mellitus type 2 (order of the Ministry of Healthcare of Ukraine dated 21.12.2012 № 1118), which identifies 4 quality indicators, is b...
Rational Prescribing of Sulfonylurea in Patients with Diabetes Mellitus Type 2
No abstract
Prognostic Value of Proteolysis Indexes in the Formation of Diabetic Retinopathy
The article presents the results of the study on the violations in the proteolysis system of patients with type 2 diabetes mellitus (DM) and diabetic retinopathy (DR). We have evaluated the levels of matrix metalloprotei...
Condition of locomotor system in patients with diabetes mellitus
Article contains modern aspects on the pathology of locomotor system in patients suffering from diabetes mellitus type 1 and type 2, in particular, pathophysiologic mechanisms of bone tissue damage by hyperglycemia, as w...
Apelin Role in the Development of Glucose Metabolism Disorders (Review of the Literature and Our Own Researches)
The physiological and pathogenetic role of adipokine apelin, endogenous ligand of apelin (APJ or APLNR) receptors in the development of glucose metabolism disorders has been analyzed. Established correlations of apelin w...